Skip to Main Content
Contribute Try STAT+ Today

Just days before Pfizer (PFE) announced plans to acquire Medivation six years ago, the former head of business development at Medivation bought stock in yet another company that Wall Street bankers deemed equally desirable. Now, he has been charged with insider trading by the U.S. Securities and Exchange Commission.

In a complaint filed in federal court, the agency alleged Matthew Panuwat used confidential information he acquired at Medivation to purchase stock options in Incyte (INCY) “within minutes” of learning about the pending deal, because he anticipated that it would likely lead to an increase in Incyte’s stock price. After the deal was announced, Incyte stock rose about 8% and he earned $107,066 in “illicit profits.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment